Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALKBH5 | Q6P6C2 | 3/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493299 | 0.85 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1667886 | 0.85 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1493441 | 0.84 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5057080 | 0.81 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL30737522 | 0.78 | ALKBH5 (0.59) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL1493300 | 0.78 | CYP2A6 (0.50) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1493260 | 0.77 | FYN (0.44) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1493264 | 0.76 | CHEK1 (0.43) | — | |
| SCHEMBL1493371 | 0.76 | ALKBH5 (0.63) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5062777 | 0.76 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | NPC1 2144/4885RAB9A 787/4885SMN1; SMN2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.